… then assessed against molecular targets: BCR-ABL1 ≤10%, ≤1… to imatinib 800 mg/day,
and subsequently switched to nilotinib … Cohort 2 patients failing any target switched to nilotinib …

… imatinib in targeting CNS BCR-ABL + leukemia despite poor csf penetration. Our experience
of nilotinib treatment in BCR-ABL + -… relevant activity of nilotinib in BCR-ABL + CNS relapse …

… The BCR-ABL inhibitor imatinib revolutionized the treatment … However, resistance and
intolerance to imatinib have … BCR-ABL, increased production of BCR-ABL, or activation of …

… Nilotinib Efficacy and Safety in Clinical Trials–Newly Diagnosed Pts) trial, nilotinib demonstrated
superior efficacy vs imatinib in … and BCR-ABL mutation status in pts from ENESTnd. …

… This study aimed to investigate the safety and efficacy of switching to nilotinib vs imatinib
dose escalation for patients with suboptimal cytogenetic response on imatinib. …

… Of 98 patients who had developed resistance to second-line therapy with dasatinib or
nilotinib administered after imatinib failure, 76 (78%) were positive for BCR-ABL KD mutations. A …

… had received imatinib followed by dasatinib and/or nilotinib. … CML that was imatinib-resistant
(≥600 mg/day) or imatinib-… nilotinib 800 mg/day (IM + N − R), or intolerant to any dose of …

… nilotinib, a more potent BCR-ABL … nilotinib and imatinib on BCR-ABL TK activity. Although
the maximal inhibition of CRKL phosphorylation by nilotinib and imatinib was similar, nilotinib …

… -resistant BCR-ABL mutants, but has no significant activity against the T315I mutant in vitro.
… of patients with imatinib resistant or intolerant CML or Ph+ ALL treated with nilotinib in an …

… that selectively targeting BCR-ABL with nilotinib is an important therapeutic option for patients
who have progressed to advanced phase Ph+ CML. Nilotinib treatment resulted in a high …